Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo

2835.305 - 2857.119 Dr. Andrea Apolo

So there's the EV304 study for patients that are cisplatinum eligible where they get EV plus PEMBRO and in the neoadjuvant setting, and then they get it in the adjuvant setting, and then there's the control arm study. that just get neoadjuvant cisplatinum-based chemotherapy and nothing in the adjuvant setting. And then we saw a little bit of data from the Volga study at ESMO.